Sneha Suresh

Dr. Sneha Suresh

University of Alberta
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2019 in Pediatric Transplantation
Verified
Journal Article
Closed access
PDF file
SSSneha Suresh
Sneha Suresh
JUJulia Upton
Julia Upton
MGMichael Green
Michael Green
APAnne Pham‐Huy
Anne Pham‐Huy
KPKlara M. Posfay‐Barbe
Klara M. Posfay‐Barbe
UAUpton D. Allen
Upton D. Allen

12 October 2017 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
SSSneha Suresh
Sneha Suresh
SFSarah Forgie
Sarah Forgie
JRJoan Louise Robinson
Joan Louise Robinson

Verified
Journal Article
Open access
PDF file
RCRaymond Chu
Raymond Chu
CECharmaine van Eeden
Charmaine van Eeden
SSSneha Suresh
Sneha Suresh
WSWendy I. Sligl
Wendy I. Sligl
MOMohammed S. Osman
Mohammed S. Osman
Jan Willem Cohen TervaertJan Willem Cohen Tervaert
Jan Willem Cohen Tervaert
The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in significant morbidity and mortality across the world, with no current effective treatments available. Recent studies suggest the possibility of a cytokine storm associated with severe COVID-19, similar to the biochemical profile seen in hemophagocytic lymphohistiocytosis (HLH), raising the question of possible benefits that could be derived from targeted immunosuppression in severe COVID-19 patients. We reviewed the literature regarding the diagnosis and features of HLH, particularly secondary HLH, and aimed to identify gaps in the literature to truly clarify the existence of a COVID-19 associated HLH. Diagnostic criteria such as HScore or HLH-2004 may have suboptimal performance in identifying COVID-19 HLH-like presentations, and criteria such as soluble CD163, NK cell activity, or other novel biomarkers may be more useful in identifying this entity.

26 August 2016 in Pediatric Transplantation
Verified
Journal Article
Closed access
PDF file
SSSneha Suresh
Sneha Suresh
BLBonita E. Lee
Bonita E. Lee
JRJoan Louise Robinson
Joan Louise Robinson
MAMichael S. Akinwumi
Michael S. Akinwumi
JPJutta K. Preiksaitis
Jutta K. Preiksaitis

1 February 2020 in The Journal of Allergy and Clinical Immunology: In Practice
Verified
Journal Article
Closed access
SSSneha Suresh
Sneha Suresh
HDHarjit Dadi
Harjit Dadi
BRBrenda Reid
Brenda Reid
LVLinda Vong
Linda Vong
DBDennis E. Bulman
Dennis E. Bulman
CRChaim M Roifman
Chaim M Roifman

28 June 2016 in JMM Case Reports
Verified
Journal Article
Open access
SSSneha Suresh
Sneha Suresh
GTGregory Tyrrell
Gregory Tyrrell
AAAreej Alhhazami
Areej Alhhazami
SESandra Escoredo
Sandra Escoredo
MHMichael Hawkes
Michael Hawkes
Introduction: Late-onset disease with Group B Streptococcus (GBS LOD) remains a significant problem in neonates. Unlike early-onset disease, rates of GBS LOD have not changed with prenatal testing. Effects of GBS LOD can be severe and thus identifying risk factors for severe GBS LOD, such as hypervirulence genes, may help in managing these infants. Case presentation: We present a case of a neonate with capsular serotype III GBS sepsis without meningitis that recurred 6 days after a 10-day-treatment period with IV ampicillin. The second episode was characterized by sepsis, neuroinvasion, meningitis and subsequent profound encephalomalacia. The short duration between the two episodes suggested recrudescence rather than reinfection. The GBS isolate was ultimately found to be positive for hypervirulence gene hvgA+, which encodes for a protein known to mediate meningeal tropism and neuroinvasion. Conclusion: hvgA positivity may thus potentially serve as an important biomarker for severe and neuroinvasive GBS LOD that can influence treatment decisions.